ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

FUM Futura Medical Plc

40.00
-0.30 (-0.74%)
18 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.30 -0.74% 40.00 297,713 16:35:09
Bid Price Offer Price High Price Low Price Open Price
39.30 39.90 40.00 39.20 40.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations -5.85M -0.0194 -20.57 119.98M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:55:53 O 478 40.002 GBX

Futura Medical (FUM) Latest News

Futura Medical (FUM) Discussions and Chat

Futura Medical Forums and Chat

Date Time Title Posts
18/3/202418:52FUTURA a winner for 201520,791
02/3/202411:36FUM this ones bound to rise!93
31/10/202315:48fum value1
02/7/202309:15Quiet on here 34
12/6/202316:18FUTURA - FDA Approval Due in 20234

Add a New Thread

Futura Medical (FUM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-03-18 16:55:5440.00478191.21O
2024-03-18 16:35:0940.00478191.20UT
2024-03-18 16:11:3139.388,5723,376.00O
2024-03-18 16:07:5839.655,0441,999.94O
2024-03-18 15:50:5939.651,646652.64O

Futura Medical (FUM) Top Chat Posts

Top Posts
Posted at 18/3/2024 08:20 by Futura Medical Daily Update
Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 40.30p.
Futura Medical currently has 300,712,293 shares in issue. The market capitalisation of Futura Medical is £119,984,205.
Futura Medical has a price to earnings ratio (PE ratio) of -20.57.
This morning FUM shares opened at 40p
Posted at 28/2/2024 11:41 by takeiteasy
Today has proved my theory that the higher the price above 40p the greater the sense of panic in the camp and I see we have 3 cut and paste jobs in a row on the other thread - that are fortunately filtered.

When we get the share price over 50p he will be up to post every half hour I suspect :)
Posted at 20/2/2024 15:12 by broomrigg
Don't worry he makes no difference to the share price or the worldwide rollout of Eroxon.
Posted at 14/2/2024 14:16 by seagreen
Well it seems the gel is working on the share price.
Thank you for your kind observations, but you chose to ignore the most crucial point that the side effects on some of viagra etc are pretty darn unpleasant.

So as the NHS views ED can cause depression etc, which is increasingly focused on, all the patients who suffer unpleasant side effects have to do is explain it to their GP that they would like to try Eroxon instead and they will presumably prescribe it.
Posted at 06/2/2024 15:47 by keifer derrin
Dermsys is the base product and in the early days, FUM added a drug to dermasys for ED.

Unusally for the Phase III trail the authorities made FUM use dermasys as the plecebo. Normally they would have used another inert gel product

When the test was released it appeared that dermasys worked the same as with the added drug. Which was it worked in 60% of males. Hence why it appears that it was the same as a placebo

As they didn't need to use the added "drug" it allowed FUM to proceed down the current route without having to do any extra tests.

Although the FDA made FUM do some other testing on African Americans and that it worked over a period of time. From this test FUM also found that the longer they used the product the better the erection

(edited to add extra to post
Posted at 06/2/2024 10:20 by 2 solaris
Thanks genierub for your post on HE1 which alerted me to this share. I top sliced there and put the profits here as I think this is going to be massive and over a decent period of time. It will be worldwide in the near future and the share price will act accordingly. In my opinion of course.
Posted at 06/2/2024 08:34 by oxford43
Sales would be £3.6m and have beaten £3.4m if the £0.5m had not been delayed to Jan. If US gets going 2024 could be a transformational year for FUM and share price
Posted at 10/1/2024 13:49 by petroc
Welcome to the world of FUM, Phatty! The share price never does what you expect it to!
Posted at 22/12/2023 10:06 by goldie40
mdi petro still in study mode oral pill form but must admit worried about share price decline of fum need news of progress of sales with amazon boots etc urgent update needed
Posted at 13/10/2023 17:06 by mdi
The first RNS regarding the Co High Chinese collaboration was 4/3/2021. The shares traded through 36p on 19/3/2021 on still unexplained very high volumes of over 36m shares trading on that day alone in March 2021. So the share price is back to where it was in March 2021 and anyone who bought in the market above the current share price of 36p over the last two and half years has lost money on those shares. The Co High exercising their warrants RNS was 1/4/2021 at 22p and the conversion of the Chinese collaboration convertible loan notes into 7.5m FUM shares at 20p was 15/4/2023. So Co High can keep selling those 20p shares into the market. Just like the Directors and employees who recently got 20p options can sell them all the way back down to 20p and still be in the money. With the small retail investors having to average down and be left sitting on more losses. While Co High and FUM Directors/employees continue to be able to sell out their millions of 20p shares making money at their expense until Haleon makes its announcement in ‘due course’ on the ‘ongoing regulatory development’ requirement for USA. Unlike with what happened with Co High and the exact reasons for why Eroxon failed to progress in China. Haleon is a public company so the detail and outcome of any ‘pivotal study’ ie double blind placebo controlled on Eroxon will eventually be made public.

‘Haleon is responsible for the future launch and ongoing regulatory, development, marketing, and commercialization of MED3000 in the USA. Further details will be disclosed in due course’
Posted at 13/10/2023 16:09 by mdi
If you go back to the RNS dated 4/3/2021. Guess what the share price was around that day. 36p. So FUM are back to the share price obtained two and a half years ago. Co High got just under 9m shares for 20p but since then there was some unexplained collapse of this Chinese agreement with FUM. Many now saying its High Co who has been selling their remaining shareholding. Did the Chinese require the same ‘pivotal study’ as required by the FTC ie a pivotal double blind placebo controlled?

‘This is expected to include a pivotal study in order to gain OTC regulatory approval within China’

Is that why Co High are selling out before it’s announced about the Haleon study that also is now required?

‘China and South East Asia - Termination of commercial agreement

In March 2021 Futura announced a Joint Collaboration with Co-High for the regulatory development, approval and commercialisation of MED3000 in South East Asia. Unfortunately, this collaboration has not progressed as Futura had hoped’
Futura Medical share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com